Scarica l'app Stockscreener
1.31
5.65%
0.07
Dopo l'orario di chiusura:
1.29
-0.02
-1.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.24
Aprire:
$1.26
Volume 24 ore:
157.89K
Relative Volume:
0.76
Capitalizzazione di mercato:
$82.91M
Reddito:
-
Utile/perdita netta:
$-45.08M
Rapporto P/E:
-1.7945
EPS:
-0.73
Flusso di cassa netto:
$-33.68M
1 W Prestazione:
+2.34%
1M Prestazione:
+4.80%
6M Prestazione:
-54.67%
1 anno Prestazione:
-51.84%
Intervallo 1D:
$1.245
$1.3298
Intervallo di 1 settimana:
$1.22
$1.36
Portata 52W:
$0.726
$3.17
Galectin Therapeutics Inc Stock (GALT) Company Profile
Nome
Galectin Therapeutics Inc
Settore
Industria
Telefono
678-620-3186
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Confronta GALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.31 | 81.01M | 0 | -45.08M | -33.68M | -0.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-13 | Iniziato | B. Riley FBR | Buy |
| 2017-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-19 | Iniziato | ROTH Capital | Buy |
| 2017-03-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Downgrade | ROTH Capital | Buy → Sell |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-09-21 | Iniziato | H.C. Wainwright | Buy |
| 2014-08-01 | Downgrade | Aegis Capital | Buy → Hold |
| 2014-07-30 | Reiterato | MLV & Co | Buy |
| 2014-07-29 | Reiterato | MLV & Co | Buy |
| 2014-04-02 | Reiterato | MLV & Co | Buy |
| 2014-02-10 | Reiterato | Aegis Capital | Buy |
| 2014-01-09 | Reiterato | Aegis Capital | Buy |
| 2013-12-03 | Iniziato | MLV & Co | Buy |
| 2013-08-19 | Reiterato | Aegis Capital | Buy |
Mostra tutto
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister
Portal Hypertension Market Growth Projections 2023-2032: - openPR.com
MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter
9 Short Squeeze Stocks That Could Take Off - US News Money
Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail
Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail
CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail
MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter
HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World
HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
SPY ETF News, 4/3/2025 - The Globe and Mail
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World
Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):